MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec for the Treatment of X-linked Retinitis Pigmentosa
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
Syntholene Energy Corp. Appoints Former Suncor, Shell Operations Executive Marc Mageau to Advisory Board
Angkor Resources' Subsidiary Implements Playgrounds For Rural Schools In Block VIII Drilling Area, Cambodia
